RNY1P9

Across TCGA pan-cancer cohorts, RNY1P9 RNA is linked to patient survival in 22 of 34 cancer types, making it the most broadly survival-associated RNY1P9 data layer.

The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where higher RNY1P9 RNA is associated with worse disease-free survival. In most high-consensus cancer types, elevated RNY1P9 expression acts as an unfavorable survival marker, although some lineages such as OV and STAD show a favorable association.

KIRC, ACC, and COAD are the cancer types where RNY1P9 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
KIRC	DFS	Median	III,IV	0.334	0.587	<.001	81	view →
ACC	DFS	Tertile	All	0.340	0.663	<.001	76	view →
COAD	OS	Tertile	IV	0.227	0.649	.003	65	view →
UCEC	OS	Quartile	III,IV	0.389	0.698	.004	60	view →
OV	OS	Median	All	0.738	0.642	.002	58	view →
STAD	DFS	Quartile	All	0.678	0.346	.004	47	view →
LUAD	DFS	Tertile	II,III,IV	0.525	0.109	.006	30	view →
CHOL	DFS	Median	II,III,IV	0.145	0.564	.003	21	view →
READ	OS	Tertile	III,IV	0.375	0.881	.004	21	view →
GBM	OS	Median	All	0.213	0.321	.011	15	view →
SKCM	OS	Median	IV	1.000	0.257	.001	15	view →
LUSC	OS	Median	III,IV	0.539	0.916	.006	10	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 22 lineages.

RNY1P9–KIRC (DFS)

Open the KIRC breakdown →